Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 117330
1. Kuusk T, Pulliainen K, Vaarala MH: External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients. Mol Clin Oncol; 2017 Mar;6(3):428-432
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
  • Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castration-resistant prostate cancer.
  • However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established.
  • In the present retrospective, single-institutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease.
  • Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated.
  • A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT.
  • Prostate-specific survival time was negatively associated with the Gleason score at diagnosis.
  • The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival.
  • Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival.
  • Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited.
  • However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2015 Sep;68(3):386-96 [25484142.001]
  • [Cites] J Cancer Res Clin Oncol. 2013 Nov;139(11):1955-60 [24057645.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3141-5 [15510602.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e205-11 [22342096.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Urol. 1999 Apr;6(4):187-91 [10226836.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1962-8 [15774789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65 [19327908.001]
  • [Cites] BJU Int. 2009 Nov;104(10):1462-6 [19522869.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):264-8 [15170145.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):907-12 [7591901.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2015 Jan;27(1):16-21 [25445554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9 [15145150.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2918-25 [15860850.001]
  • (PMID = 28451427.001).
  • [ISSN] 2049-9450
  • [Journal-full-title] Molecular and clinical oncology
  • [ISO-abbreviation] Mol Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; prostate cancer / radiation / retrospective chart review
  •  go-up   go-down


2. Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P: The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiat Oncol; 2017 Mar 09;12(1):50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.
  • BACKGROUND: This study aimed to investigate the tolerability and impact of milk of magnesia (MoM) on interfraction rectal filling during prostate cancer radiotherapy.
  • METHODS: Two groups were retrospectively identified, each consisting of 40 patients with prostate cancer treated with radiotherapy to prostate+/-seminal vesicles, with daily image-guidance in 78Gy/39fractions/8 weeks.
  • [MeSH-major] Artifacts. Intestine, Small / physiology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Image-Guided / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1611-21 [15590193.001]
  • [Cites] Eur Urol. 2011 Dec;60(6):1133-9 [21889832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):277-82 [20451274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):456-66 [18374517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1072-8 [19783378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53 [16545919.001]
  • [Cites] Strahlenther Onkol. 2014 Aug;190(8):758-61 [24760248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33 [10348281.001]
  • [Cites] Radiother Oncol. 2011 Dec;101(3):471-8 [21903283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):646-50 [24054874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1418-24 [17241751.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):225-34 [10368047.001]
  • [Cites] Jpn J Radiol. 2009 Jun;27(5):205-12 [19554413.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1279-86 [18572088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73 [15989996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18 [19616743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):653-60 [22099039.001]
  • [Cites] Acta Oncol. 2014 Apr;53(4):569-71 [24237391.001]
  • (PMID = 28279179.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Laxatives
  • [Keywords] NOTNLM ; Bowel preparation / Laxative / Prostate cancer / Radiotherapy / Rectum
  •  go-up   go-down


3. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol; 2017;7:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
  • BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone.
  • MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol.
  • Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy.
  • Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2010 Oct;9(5):453-62 [20815416.001]
  • [Cites] Front Oncol. 2016 May 06;6:114 [27200300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4 [16111583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9 [26530768.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):285-95 [9572622.001]
  • [Cites] J Urol. 2015 Dec;194(6):1624-30 [26165583.001]
  • [Cites] Radiat Oncol. 2016 Jan 21;11:8 [26792201.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8 [20207506.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):575-82 [21070079.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1192-9 [15718316.001]
  • [Cites] Radiother Oncol. 2012 Jul;104(1):114-8 [22727264.001]
  • [Cites] Radiat Oncol. 2013 Mar 13;8:58 [23497695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1990-6 [16648499.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Acta Oncol. 2005;44(3):265-76 [16076699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 [12023135.001]
  • [Cites] Cancer. 2015 Jul 15;121(14):2422-30 [25847819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007 [16750320.001]
  • [Cites] Urology. 2000 Mar;55(3):382-6 [10699615.001]
  • [Cites] Radiat Oncol. 2013 Jan 31;8:30 [23369294.001]
  • [Cites] Radiother Oncol. 2012 May;103(2):217-22 [22341794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 [21300474.001]
  • [Cites] Cancer. 2013 Feb 1;119(3):681-90 [22893254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7 [18947938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2630-7 [10375112.001]
  • [Cites] J Urol. 2016 Jun;195(6):1811-6 [26778712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85 [22954770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53 [27325475.001]
  • [Cites] Radiother Oncol. 2000 Jan;54(1):11-9 [10719695.001]
  • [Cites] Radiat Oncol. 2014 Jan 01;9:1 [24382205.001]
  • [Cites] Br J Radiol. 2015 Oct;88(1054):20140736 [26235142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7 [26054865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8 [24113055.001]
  • [Cites] Front Oncol. 2014 Oct 31;4:278 [25401085.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7 [14610406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16 [15817332.001]
  • [Cites] Radiat Oncol. 2014 Dec 12;9:277 [25497602.001]
  • [Cites] Radiother Oncol. 2009 May;91(2):232-6 [19097660.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Front Oncol. 2015 Sep 01;5:194 [26389077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91 [12694837.001]
  • [Cites] J Urol. 2007 Jan;177(1):123-7; discussion 127 [17162020.001]
  • (PMID = 28224113.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CyberKnife / IMRT / SBRT / common terminology criteria / prostate cancer
  •  go-up   go-down


Advertisement
4. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


5. Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT: Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. Med Decis Making; 2017 Oct;37(7):815-826
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
  • BACKGROUND: New cancer biomarkers are being discovered at a rapid pace; however, these tests vary in their predictive performance characteristics, and it is unclear how best to use them.
  • METHODS: We investigated 2-stage biomarker-based screening strategies in the context of prostate cancer using a partially observable Markov model to simulate patients' progression through prostate cancer states to mortality from prostate cancer or other causes.
  • If the patient's serum prostate-specific antigen (PSA) was over a specified threshold in the first stage, a second stage biomarker test was administered.
  • Monte Carlo simulation was used to estimate the number of screening biopsies, prostate cancer deaths, and quality-adjusted life-years (QALYs) per 1000 men.
  • RESULTS: The all-cancer biomarkers significantly underperformed the high-grade cancer biomarkers in terms of QALYs.
  • This strategy resulted in a prostate cancer death rate within 1% of using PSA alone with a threshold of 2 ng/mL, while reducing the number of biopsies by 20%.
  • CONCLUSIONS: Two-stage biomarker screening strategies using new biomarkers with risk thresholds optimized for high-grade cancer detection may increase quality-adjusted survival and reduce unnecessary biopsies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28363265.001).
  • [ISSN] 1552-681X
  • [Journal-full-title] Medical decision making : an international journal of the Society for Medical Decision Making
  • [ISO-abbreviation] Med Decis Making
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Biomarkers / Markov Model / Prostate Cancer / Simulation
  •  go-up   go-down


6. Shahinian VB, Kaufman SR, Yan P, Herrel LA, Borza T, Hollenbeck BK: Reimbursement and use of intensity-modulated radiation therapy for prostate cancer. Medicine (Baltimore); 2017 Jun;96(25):e6929

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reimbursement and use of intensity-modulated radiation therapy for prostate cancer.
  • The use of intensity-modulated radiation therapy (IMRT) for prostate cancer increased through the mid-2000s, in association with acquisition of the devices by large urology groups.
  • The aim of the study was to examine trends in IMRT use and related payments in the office versus hospital outpatient setting over time.In this retrospective cohort study, a total of 66,967 men aged 66 years or older, with newly diagnosed prostate cancer from 2007 through 2012 were identified in a 20% national sample of Medicare claims.
  • Mean reimbursement for IMRT treatments and total IMRT-related payments were plotted by year.IMRT use increased from 28.6% to 38.0% of newly diagnosed men with prostate cancer over the study period, exclusively related to growth in the office setting.
  • However, total IMRT-related payments in the office setting increased through 2011 due to increased utilization, falling only in 2012 (to $35.7 million from $48.3 million in 2011) related both to continued declines in reimbursement and a large reduction in new cases of prostate cancer.In conclusion, use of IMRT in the physician office setting in men diagnosed with prostate cancer has continued to increase in the face of declining reimbursement.
  • Total payments for IMRT fell only in 2012, following a substantial reduction in new cases of prostate cancer.
  • [MeSH-major] Ambulatory Care Facilities / economics. Insurance, Health, Reimbursement. Medicare. Prostatic Neoplasms / economics. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / economics. Radiotherapy, Intensity-Modulated / utilization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2011 Apr 20;29(12):1517-24 [21402604.001]
  • [Cites] N Engl J Med. 2010 Nov 4;363(19):1822-32 [21047226.001]
  • [Cites] J Clin Oncol. 2010 Mar 1;28(7):1117-23 [20124165.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] J Health Econ. 1982 Dec;1(3):231-44 [10263957.001]
  • [Cites] Med Care. 1983 Aug;21(8):803-15 [6350746.001]
  • [Cites] J Hum Resour. 1978;13 Suppl:35-56 [722069.001]
  • [Cites] Ann Intern Med. 2012 Jul 17;157(2):120-34 [22801674.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):975-80 [9749479.001]
  • [Cites] J Health Econ. 1986 Dec;5(4):293-313 [10317903.001]
  • [Cites] N Engl J Med. 2001 Jul 12;345(2):99-106 [11450679.001]
  • [Cites] JAMA. 2013 Jun 26;309(24):2587-95 [23800935.001]
  • [Cites] Health Serv Res. 1997 Aug;32(3):283-98 [9240281.001]
  • [Cites] N Engl J Med. 2013 Oct 24;369(17):1629-37 [24152262.001]
  • [Cites] J Natl Cancer Inst. 2011 May 18;103(10):798-809 [21525437.001]
  • [Cites] J Health Econ. 1998 Dec;17(6):675-99 [10339248.001]
  • [Cites] Int J Epidemiol. 2014 Jun;43(3):962-70 [24603316.001]
  • [Cites] Health Aff (Millwood). 2010 Jul;29(7):1391-9 [20558507.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7881-8 [16204005.001]
  • [Cites] CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 [26742998.001]
  • [Cites] Ann Intern Med. 1996 Mar 15;124(6):577-84 [8597322.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • (PMID = 28640073.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA168691; United States / NCI NIH HHS / CA / T32 CA180984
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Shahriari M, Dehghan M, Pahlavanzadeh S, Hazini A: Effects of progressive muscle relaxation, guided imagery and deep diaphragmatic breathing on quality of life in elderly with breast or prostate cancer. J Educ Health Promot; 2017;6:1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of progressive muscle relaxation, guided imagery and deep diaphragmatic breathing on quality of life in elderly with breast or prostate cancer.
  • BACKGROUND AND OBJECTIVES: Due to the increasing number of elderly and an increase in the number of cases of cancer by age, cancer is a common problem in the elderly.
  • For elderly patients with cancer, the disease and its treatment can have long-term negative effects on their quality of life (QoL).
  • The purpose of this study was to evaluate the effect of progressive muscle relaxation, body image and deep diaphragmatic breathing on the QoL in the elderly with cancer.
  • MATERIALS AND METHODS: This study was a randomized controlled trial in which 50 elderly patients with breast or prostate cancer were randomized into study and control groups.
  • European Organization for Research and Treatment of Cancer and QoL Questionnaire-Core questionnaires was completed before, after and 6 weeks after the intervention for the patients in both groups simultaneously.
  • CONCLUSIONS: The findings indicated that concurrent application of progressive muscle relaxation, guided imagery, and deep diaphragmatic breathing would improve QoL in the elderly with breast or prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Forum. 2006 Apr-Jun;41(2):60-77 [16669984.001]
  • [Cites] Indian J Med Res. 2009 May;129(5):603-8 [19675392.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1944-51 [12743147.001]
  • [Cites] Psychooncology. 2007 Nov;16(11):971-9 [17311247.001]
  • [Cites] Complement Ther Clin Pract. 2008 Aug;14(3):185-94 [18640630.001]
  • [Cites] J Child Psychol Psychiatry. 2004 Oct;45(7):1199-208 [15335340.001]
  • [Cites] CA Cancer J Clin. 2013 Jan;63(1):11-30 [23335087.001]
  • [Cites] Support Care Cancer. 2005 Oct;13(10):826-33 [15856335.001]
  • [Cites] Psychooncology. 2003 Apr-May;12(3):254-66 [12673809.001]
  • [Cites] Cancer Nurs. 2002 Dec;25(6):432-5 [12464834.001]
  • [Cites] J Pain Symptom Manage. 2010 Jan;39(1):126-38 [19900778.001]
  • [Cites] Ann Oncol. 2010 May;21 Suppl 3:iii83-89 [20427365.001]
  • [Cites] Support Care Cancer. 2002 Apr;10(3):237-46 [11904789.001]
  • [Cites] Cancer. 2009 Sep 15;115(18 Suppl):4283-97 [19731348.001]
  • [Cites] Support Cancer Ther. 2007 Sep 1;4(4):247-50 [18632524.001]
  • (PMID = 28546966.001).
  • [ISSN] 2277-9531
  • [Journal-full-title] Journal of education and health promotion
  • [ISO-abbreviation] J Educ Health Promot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Cancer / diaphragmatic breathing / elderly / guided imagery / progressive muscle relaxation / quality of life
  •  go-up   go-down


8. Williams F, Imm KR, Colditz GA, Housten AJ, Yang L, Gilbert KL, Drake BF: Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. Support Care Cancer; 2017 Apr;25(4):1151-1158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer.
  • PURPOSE: Physical activity is recognized as a complementary therapy to improve physical and physiological functions among prostate cancer survivors.
  • Little is known about communication between health providers and African-American prostate cancer patients, a high risk population, regarding the health benefits of regular physical activity on their prognosis and recovery.
  • This study explores African-American prostate cancer survivors' experiences with physical activity prescription from their physicians.
  • METHODS: Three focus group interviews were conducted with 12 African-American prostate cancer survivors in May 2014 in St. Louis, MO.
  • These findings highlight the importance of physical activity communication and prescription for prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27999951.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; African-American / Physical activity / Physician / Prescription/communication / Prostate cancer / Survivor
  •  go-up   go-down


9. Griebling TL: Re: Survival after Conservative Management versus External Beam Radiation Therapy in Elderly Patients with Localized Prostate Cancer. J Urol; 2017 Jan;197(1):157-158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Survival after Conservative Management versus External Beam Radiation Therapy in Elderly Patients with Localized Prostate Cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27979516.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. García-Vicente F, Zapatero A, Floriano A, Cruz-Conde A, Pérez L, Marín A, Mínguez C, Torres JJ: Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer. Med Phys; 2005 Aug;32(8):2503-2509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer.
  • The purpose of this paper is to determine the correlation between dose-volume histogram (DVH) and dose wall-histogram (DWH) in the evaluation of rectal complications for prostate cancer patients treated with three-dimensional conformal radiotherapy (3D-CRT).
  • A retrospective analysis of DVHs and DWHs of a subset of 25 prostate cancer patients treated with 3D-CRT was performed.
  • The present study confirms a high correlation (>80%) between DVH and DWH of the rectum following 3D-CRT for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28523870.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Biomedical modeling / Cancer / Computed tomography / Conformal radiation treatment / Diseases / Dosimetry / Medical treatment planning / Probability theory, stochastic processes, and statistics / Radiation therapy / Radiation treatment / Statistical analysis / Therapeutics / Treatment strategy / biological organs / cancer / dosimetry / radiation therapy / regression analysis / tumours
  •  go-up   go-down






Advertisement